Expanding its portfolio of innovative health solutions, the Inova Personalized Health Accelerator (IPHA) has invested in a new therapy company that is developing a solution to address a major unmet need in patients with olfactory impairment. Sense of smell can often be taken for granted, until it is lost. This occurs most commonly by sino-nasal disease and upper respiratory infection, and in many cases, by head trauma. Cyrano Therapeutics understands the profound impact these senses can have on quality of life and is developing the first safe and effective nasal spray to restore and maintain the sense of smell and its connection with the ability to detect flavor in food (often perceived as taste). According to the peer-reviewed journal BMC Ear, Nose and Throat Disorders, 14 million patients in the United States have olfactory impairment or loss of smell, yet few treatments are available.